Enanta Pharmaceuticals, Inc. (ENTA)

Market Cap	281.80M
Revenue (ttm)	73.62M
Net Income (ttm)	-138.24M
Shares Out	21.16M
EPS (ttm)	-6.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,813
Open	13.10
Previous Close	13.23
Day's Range	12.77 - 13.44
52-Week Range	8.08 - 37.75
Beta	0.49
Analysts	Hold
Price Target	19.33 (+45.12%)
Earnings Date	May 6, 2024

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the ma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 21, 2013
• Employees: 145
• Stock Exchange: NASDAQ
• Ticker Symbol: ENTA

Financial Performance

In 2023, ENTA's revenue was $79.20 million, a decrease of -8.07% compared to the previous year's $86.16 million. Losses were -$133.82 million, 9.91% more than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for ENTA stock is "Hold." The 12-month stock price forecast is $19.33, which is an increase of 45.12% from the latest price.

Price Target

$19.33

(45.12% upside)

Analyst Consensus: Hold